Sunday, November 1, 2026

Moderna Stock Over 9% Down So Far Today

ViaNews Editorial Team

December 22, 2020

Moderna Stock Over 9% Down So Far Today

Shares of Moderna fell 9.81% to $124.74 at 14:50 EST on Tuesday, after two successive sessions in a row of losses. The Nasdaq Stock Market is jumping 0.48% to $12,804.00, after two consecutive sessions in a row of losses. This seems, up to now, a somewhat positive trend trading session today.

Moderna's last close was $138.30, 43.10% under its 52-week high of $178.50.

Moderna's Sales

Moderna's sales growth is 1841.7% for the present quarter and 19117.5% for the next. The company's growth estimates for the present quarter is a negative 2.7% and positive 660% for the next.

Moderna's Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's Stock Yearly Top and Bottom Value

Moderna's stock is valued at $124.74 at 14:50 EST, way under its 52-week high of $178.50 and way higher than its 52-week low of $17.68.

Moderna's Moving Average

Moderna's value is higher than its 50-day moving average of $116.47 and way higher than its 200-day moving average of $80.87.

Previous days news about Moderna

Moderna shot cleared in U.S., boosting immunization effort. According to Bloomberg Quint on Sat Dec 19, "Overall, Moderna and manufacturing partner Lonza Group AG plan to produce 500 million to 1 billion total doses of its vaccine in 2021. ", "Developed with the National Institutes of Health, Moderna's shot, like the one produced by Pfizer Inc. and BioNTech SE that was cleared last week, is based on messenger RNA technology that previously hadn't been used in vaccines. "

Moderna, Exxon, Alphabet, Amazon: stocks that defined the week. According to The Wall Street Journal on Sat Dec 19, "Moderna, a ten-year-old biotech that has never had a product cleared by the FDA, expects to deliver a total of 20 million doses by the end of December. ", "U.S. health regulators late Friday permitted use of Moderna's Covid-19 vaccine, the second shot to get the green light to help end the pandemic. "

Statement on the U.S. authorization of the Moderna Covid-19 vaccine. According to Business Insider on Sat Dec 19, "Health Canada has been reviewing Moderna's vaccine since it was submitted on October 12, 2020, and is expediting the review of COVID-19 vaccines. ", "OTTAWA, ON, Dec. 18, 2020 /CNW/ -Health Canada is aware that the U.S. Food and Drug Administration has issued an emergency use authorization for a COVID-19 vaccine manufactured by Moderna."

Moderna to begin delivery; London lockdown ordered: virus update. According to Bloomberg Quint on Sat Dec 19, "That allocation will bolster the 55.8 million doses that it will receive through a European Union plan, with a further 50.5 million doses of the Moderna Inc. due from the EU. ", "United Parcel Services will truck the newly-approved Moderna vaccine beginning Sunday morning from Mckesson's Kentucky facility to the courier's nearby main U.S. air hub in Louisville, Kentucky. "

Philippines to start vaccine talks with Moderna by year-end: CNN. According to Bloomberg Quint on Mon Dec 21, "The Philippines will start talks with Moderna Inc. on or before Dec. 30 to secure supply of the company's coronavirus vaccine, Foreign Affairs Secretary Teodoro Locsin said Monday.", ""Moderna is interested in giving an allocation," he said in a live-streamed interview with CNN Philippines, citing Philippine ambassador to the U.S. Jose Manuel Romualdez."

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Goes Operational: Platform Governance, Local Silicon, and the Physical-AI Data Race
In mid-to-late October 2026, enterprise vendors (Cisco, Fortinet, ServiceNow, Intuit, Salesforce/Braze, Adobe) shipped agent governance, AI security and AI-driven customer engagement products, while a parallel hardware wave (NVIDIA RTX Spark laptops, ASUS, Apple's iPad mini, Microsoft's hybrid local/cloud Windows) pushed AI onto local devices. A third strand, physical AI (Encord, Harvest Praxis, Hesai), argues that real-world sensor data and cheaper edge chips are the next bottleneck. The common thread is the shift from AI experimentation to governed, scaled deployment, with Salesforce's Braze acquisition showing consolidation and fintech players like Intuit tying AI to trusted financial data. The facts support a broad industry theme but contain little direct finance or regulatory evidence, so the AI-finance angle is thin.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,532 source documents archived
Query this data → isubstrate.com